MedTrace Logo

Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal

NCT01713153 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1365

Last updated 2016-02-25

No results posted yet for this study

Summary

This is a large, community-based, cluster-randomized trial to compare routine prophylactic use of 600 mcg oral misoprostol and 10 IU oxytocin delivered by UnijectTM intramuscularly during the third stage of labor

Conditions

  • Postpartum Hemorrhage

Interventions

DRUG

Misoprostol

600 mcg misoprostol oral

DEVICE

UnijectTM

10 IU oxytocin delivered intramuscularly with UnijectTM

Sponsors & Collaborators

  • ChildFund International

    collaborator UNKNOWN

  • Gynuity Health Projects

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Senegal

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01713153 on ClinicalTrials.gov